1-15 of 15
Authors: J M Vázquez Morón
Save search
Sort by
Journal Article

DOP038 Impact of prenatal and breastfeeding exposure to biologic drugs on the first-year anthropometric development of infants born to mothers with inflammatory bowel disease from DUMBO registry of GETECCU

PDF
L Palomino and others
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i152–i154, https://doi.org/10.1093/ecco-jcc/jjae190.0077
Published: 22 January 2025
Journal Article

P676 Unveiling the impact on in utero exposure to biologic treatments for inflammatory bowel disease (IBD) on children's psychomotor development: Insights from the DUMBO registry of GETECCU

PDF
L M Palomino Pérez and others
Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i1282–i1284, https://doi.org/10.1093/ecco-jcc/jjad212.0806
Published: 24 January 2024
Journal Article

P675 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, safety and impact of extraintestinal manifestations and immunomediated diseases

PDF
M Chaparro and others
Journal of Crohn's and Colitis, Volume 17, Issue Supplement_1, February 2023, Pages i806–i808, https://doi.org/10.1093/ecco-jcc/jjac190.0805
Published: 30 January 2023
Journal Article

P744 Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeeding

PDF
M Chaparro and others
Journal of Crohn's and Colitis, Volume 17, Issue Supplement_1, February 2023, Pages i874–i876, https://doi.org/10.1093/ecco-jcc/jjac190.0874
Published: 30 January 2023
Journal Article

P550 Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU

PDF
M Chaparro and others
Journal of Crohn's and Colitis, Volume 16, Issue Supplement_1, January 2022, Pages i496–i498, https://doi.org/10.1093/ecco-jcc/jjab232.677
Published: 21 January 2022
Journal Article

P373 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, impact of extraintestinal manifestations and immunomediated diseases and safety

PDF
M Chaparro and others
Journal of Crohn's and Colitis, Volume 16, Issue Supplement_1, January 2022, Pages i375–i377, https://doi.org/10.1093/ecco-jcc/jjab232.500
Published: 21 January 2022
Journal Article

P545 Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU

PDF
M Chaparro and others
Journal of Crohn's and Colitis, Volume 16, Issue Supplement_1, January 2022, Pages i491–i493, https://doi.org/10.1093/ecco-jcc/jjab232.672
Published: 21 January 2022
Journal Article

P478 Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy: an observational multicentre study

PDF
R Olmedo-Martín and others
Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Pages S467–S468, https://doi.org/10.1093/ecco-jcc/jjab076.601
Published: 27 May 2021
Journal Article

DOP52 Safety of Inflammatory Bowel Disease drugs during pregnancy and breastfeeding: Mothers and babies’ outcomes (DUMBO registry)

PDF
M Chaparro and others
Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Pages S086–S088, https://doi.org/10.1093/ecco-jcc/jjab073.091
Published: 27 May 2021
Journal Article

P509 Influence of concomitant immunosuppresives in retention rate in Crohn′s Disease patients under ustekinumab in the SUSTAIN Study

PDF
M Chaparro and others
Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Pages S489–S490, https://doi.org/10.1093/ecco-jcc/jjab076.631
Published: 27 May 2021
Journal Article

P313 Long-term durability and safety of anti-TNF agents compared with change to a different mechanism of action as a second-line biological treatment after first anti-TNF failure in Crohn′s disease: results from the Andalusian CambiaCrohn study

PDF
J M Vázquez Morón and others
Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Pages S339–S340, https://doi.org/10.1093/ecco-jcc/jjab076.437
Published: 27 May 2021
Journal Article

Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease Get access

PDF
M Chaparro and others
Journal of Crohn's and Colitis, Volume 13, Issue 11, November 2019, Pages 1380–1386, https://doi.org/10.1093/ecco-jcc/jjz070
Published: 12 April 2019
Journal Article

P762 Onset of inflammatory bowel disease during treatment with secukinumab: Can anti-IL-17A be a trigger for inflammatory bowel disease? Get access

PDF
R Rodríguez Moncada and others
Journal of Crohn's and Colitis, Volume 13, Issue Supplement_1, March 2019, Page S502, https://doi.org/10.1093/ecco-jcc/jjy222.886
Published: 25 January 2019
Journal Article

P519 Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: Multicentre study at 12 months results Get access

PDF
M F Guerra Veloz and others
Journal of Crohn's and Colitis, Volume 12, Issue supplement_1, February 2018, Pages S368–S369, https://doi.org/10.1093/ecco-jcc/jjx180.646
Published: 16 January 2018
Journal Article

P063 Faecal calprotectin as a non-invasive treatment target to predict mucosal healing and histological remission in asymptomatic ulcerative colitis Get access

PDF
A Correia Varela Almeida and others
Journal of Crohn's and Colitis, Volume 12, Issue supplement_1, February 2018, Pages S124–S125, https://doi.org/10.1093/ecco-jcc/jjx180.190
Published: 16 January 2018